COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UJ9N
|
|||
| Drug Name |
Promethazine
|
|||
| Synonyms |
Antiallersin; Aprobit; Avomine; Camergan; Dimapp; Diphergan; Diprazin; Diprazine; Diprozin; Fargan; Fenazil; Fenetazina; Fenetazine; Genphen; Hiberna; Histargan; Iergigan; Isophenergan; Isopromethazine; Lercigan; Lergigan; Metaryl; Pelpica; Phargan; Phenargan; Phenerzine; Phensedyl; Pilothia; Pilpophen; Pipolphene; Proazaimine; Proazamine; Procit; Promacot; Promazinamide; Promergan; Promesan; Prometasin; Prometazin; Prometazina; Prometazine; Prometh; Promethacon; Promethaine; Promethazin; PromethazineHcl; Promethazinum; Promethegan; Promethiazine; Promezathine; Prorex; Protazine; Prothazin; Prothazine; Provigan; Pyrethia; Pyrethiazine; Remsed; Romergan; Rumergan; Tanidil; Thiergan; Valergine; Vallergine; Lilly 01516; Lilly 1516; RP 3277; SKF 1498; WY 509; A-91033; Atosil (TN); Avomine (TN); Fargan (TN); Farganesse (TN); Lergigan (TN); Phenergan (TN); Phenoject-50; Pro-50; Prometazina [INN-Spanish]; Promethazine [INN:BAN]; Promethazinum [INN-Latin]; Promethegan (TN); Prothiazine (TN); Receptozine (TN); Romergan (TN); Zipan-25; Dimethylamino-isopropyl-phenthiazin; Dimethylamino-isopropyl-phenthiazin [German]; Promethazine (JAN/INN)
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Investigative | [1] | Severe acute respiratory syndrome (SARS) | Investigative | [2] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Wyeth Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H20N2S
|
|||
| Canonical SMILES |
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
|
|||
| InChI |
1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
|
|||
| InChIKey |
PWWVAXIEGOYWEE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 60-87-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9608, 89596, 616468, 5236627, 7847560, 7980398, 8153034, 10529464, 11335180, 11360419, 11363762, 11366324, 11368886, 11372096, 11374835, 11377048, 11406271, 11461391, 11466916, 11468036, 11484535, 11486631, 11488656, 11490834, 11492963, 11494682, 14848899, 24434790, 26752304, 29224005, 46507798, 47216602, 47216603, 47216604, 47290955, 47588815, 47885231, 48110274, 48184815, 48259042, 48416477, 49698886, 49854482, 50105224, 56313067, 56313700, 56459433, 57322528, 75806049, 85088938
|
|||
| ChEBI ID |
CHEBI:8461
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN clathrin-mediated endocytosis (RME) | Target Info | Inhibitor | [2] |
| Promethazine exhibits inhibitory activity against clathrin-mediated endocytosis of MERS-CoV and SARS-CoV. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. | |||
| 2 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.